California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
All content for The Big4Bio Podcast is the property of Big4Bio and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
Confessions of a Hit Man: Matching Target Strategies to the Need
The Big4Bio Podcast
37 minutes 30 seconds
1 year ago
Confessions of a Hit Man: Matching Target Strategies to the Need
For drug developers, hit identification is a critical part of the discovery of new medicines, but the proliferation of therapeutic modalities, new biological targets, and screening technologies has meant that there’s not a one-size-fits-all strategy for drug developers to pursue. We spoke to Rob Howes, Head of Discovery Sciences UK for Charles River Labs, about the need for pairing the right hit Identification strategy to a target, how hit identification is gaining importance as funding activity picks up and biopharmaceuticals turn their attention to rebuilding their early-stage pipelines, and why compelling hit identification data can attract fresh capital to a drug developer. You can learn more about Charles River Labs Hit Identification work at https://www.criver.com/products-services/discovery-services/integrated-drug-discovery/hit-identification?utm_source=big4bio&utm_medium=podcast®ion=3701
The Big4Bio Podcast
California research institutes, universities, and biopharmaceutical companies are a critical source of innovation, contributing to the development of approximately a quarter of new drugs that the U.S. Food and Drug Administration approved last year. But despite the breakthroughs, more mundane issues of tariffs, drug pricing, and access to funding continue to weigh on leaders within the sector. We spoke to Tim Scott, president and CEO of Biocom California, about the current state of the biotech industry, a surge in mergers and acquisitions driven by the looming patent cliff, and what Biocom is doing to support companies through partnerships, advocacy, and policy reform.
